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Clinics and pathology 
Disease 
Soft tissue angiofibroma 
Phenotype / cell stem origin 
Unknown. 
Embryonic origin 
Unknown. Immunohistochemical evaluation suggests a 




Presumably rare, but differential diagnostic problems 
may have hampered the distinction of these neoplasms 
in the past. The tumor occurs most frequently in 
middle-aged adults, affecting women twice as often as 
men. 
Clinics 
The tumor typically presents as a slowly growing, 
painless mass located in the soft tissue of the 
extremities, mainly the lower extremities, often in 
relation to joints or fibrotendinous structures. 
It can, however, display a broad anatomic distribution. 
The tumor is benign, with rare local recurrences and no 
evidence of metastasis potential. 
Pathology 
The tumors are most often well circumscribed, 
consisting of a patternless or vaguely lobulated spindle 
cell proliferation accompanied by a prominent vascular 
component.  
The cytomorphology is non-distinctive, characterized 
by bland fibroblastic spindle cells with a pale 
eosinophilic cytoplasm and short ovoid nuclei. There is 
no atypia. There is also a complex network of 
numerous thin-walled branching blood vessels, in 
addition to larger round or branching blood vessels. 
The stroma is variably collagenous or myxoid. 
Treatment 
Local surgical resection is an adequate treatment. 
Prognosis 
These lesions behave in a benign manner with excellent 
prognosis; few cases recur after local excision. 
Cytogenetics 
Note 
A balanced chromosome translocation t(5;8)(p15;q13) 
is a specific aberration characterizing soft tissue 
angiofibromas. This translocation was identified in five 
of six angiofibromas investigated cytogenetically; the 
sixth case had a t(7;8;14)(q11;q13;q31). 
 
Representative partial karyogram from an angiofibroma 
showing the translocation t(5;8)(p15;q13). Arrows indicate 
breakpoints. 
Cytogenetics Molecular 
In two tumors, the breakpoints of the t(5;8) were 
mapped by FISH. The breakpoints at 5p15 and 8q13 
were delineated by BAC clones RP11-1006P13, 
covering the AHRR locus, and RP11-479K21, 
harboring NCOA2, which both gave split signals. 
Interphase FISH on cut sections from nine additional 
cases of soft tissue angiofibroma using pools of BACs 
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covering AHRR and NCOA2 yielded fusion signals in 
at least 10% of the nuclei in three cases.  
Additional interphase FISH using a break-apart probe 
for the NCOA2 gene in the six fusion-negative cases 
did not reveal any split signals. 
Probes 
For metaphase FISH the BAC clones detecting the gen
fusion are RP11-1006P13 (AC113363.1), covering the 
AHRR locus, and RP11-479K21 (AQ637276.1 and 
AQ6379.1), harboring NCOA2. 
Pools of RP11-323M9 and RP11-1006P13 as well as 
RP11-479K21, RP11-746L20 (AC021558.10) and 
RP11-333A23 (AC022730.7) were used to detect 
AHRR/NCOA2 fusions in interphase nuclei. RP11-
152C15 and RP11-265O14 were used as a break-apart 
probe to detect rearrangements of NCOA2. 




DNA / RNA 
The AHRR gene consists of 12 exons with a transcript 
length of 5661 bp. It has a TATA-less promoter and 
several transcription start sites.  
The translation initiation codon is located in exon 2. 
Intron 1 contains a functional regulatory sequence 
called xenobiotic response element (XRE).  
The bHLH domain of the AHRR protein is located in 
the aminoterminal part (encoded by exon 3), followed 
by the PAS domain (exons 5 and 6). The 
carboxyterminal part has a repression domain. 
Protein 
The open reading frame of AHRR encodes a 719 amino 
acid protein, the aryl hydrocarbon receptor repressor, a 
key regulator of the activity of the aryl hydrocarbon 
receptor (AHR).  
AHR is a crucial mediator of the cellular response to 
xenobiotics such as polycyclic aromatic hydrocarbons, 
including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
better known as dioxin.  
AHRR is a putative tumor suppressor gene implicated 




DNA / RNA 
The NCOA2 gene consists of 23 exons with a transcript 
length of 8447 bp. NCOA2 has been identified as the 
3'-partner in gene fusions involved in various 
leukemias and sarcomas. 
Protein 
NCOA2, nuclear receptor co-activator 2, (also known 
as TIF2 and SRC2) is one of three members of the 
p160 steroid receptor coactivator (SRC) family.  
The protein is about 160 kDa in size and contains 1464 
aa including three structural domains. The N-terminal 
bHLH/PAS domain is the most conserved region, and 
can bind to DNA as well as heterodimerize with a 
variety of proteins with similar regions to enhance 
transcription of nuclear hormone receptor target genes.  
The central region of the SRC proteins contains three 
LXXLL motifs which interact with the nuclear 
hormone receptors. The C-terminus has two 
transcriptional activation domains (AD1 and AD2). 
AD1, also known as CREB binding protein (CREBBP) 
interacting domain (CID), binds other coactivators, 
such as CREBBP and EP300 (E1A binding protein 
p300), which leads to chromatin remodeling. AD2 is 
responsible for interaction with histone 
methyltransferases, coactivator-associated arginine 
methyltransferase 1 and PRMT1. 




The translocation t(5;8) has so far been reported in five 
soft tissue angiofibromas. Breakpoint mapping by 
metaphase FISH followed by RT-PCR has disclosed 
that this translocation results in a fusion between the 
AHRR and NCOA2 genes; in-frame AHRR/NCOA2 as 
well as NCOA2/AHRR were found in all four cases 
investigated so far. The location of the breakpoints has 
been characterized in a few cases with the t(5;8). In 
three tumors nt 1018 (the last nt of exon 9; 
NM_020731) of AHRR was joined with nt 3321 (the 
first nt of exon 16; NM_006540) of NCOA2.  
In one case, the fusion was most likely between nt 1080 
(last nt of exon 10) of AHRR and nt 2975 (first nt of 
exon 14) of NCOA2.  
As the case with the three-way t(7;8;14)(q11;q13;q31) 
resulted in a GTF2I/NCOA2 fusion, it seems 
reasonable to assume that it is the transcripts with 
NCOA2 as 3' partner that are pathogenetically relevant. 
 
Detection 
A detailed description of a protocol for the detection of 




The function of the AHRR/NCOA2 and 
NCOA2/AHRR chimeras is unknown. Based on 
previously reported fusion genes involving the p160 
SRC gene family, as well as the finding of an 
alternative GTF2I/NCOA2 fusion in one case, we 
assume that it is the AHRR/NCOA2 transcript that is 
pathogenetically significant. As the amino terminal p rt 
of the transcription factor AHRR, responsible for the 
recognition of xenobiotic response elements in target 
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genes and for heterodimerization, shows extensive 
homology with the aryl hydrocarbon receptor (AHR), 
the fusion is predicted to upregulate the AHR/ARNT 
signaling pathway. Indeed, global gene expression 
analysis showed upregulation of CYP1A1 as well as 
other typical target genes of this pathway, such as tho e 
encoding toll-like receptors. However, the relative 
impact of the reciprocal NCOA2/AHRR transcript, as 
well as of the individual domains contributed by each 
partner in the chimeric proteins, will have to be studied 
in experimental models. 
Description 
The fusion protein AHRR/NCOA2 contains the N-
terminal AHRR, i.e., the bHLH (encoded by exon 3) 
and PAS (encoded by exon 5) domains, and the C-
terminal NCOA2, including two transcriptional 
activation domains (AD1 and AD2), which replaces the
repression domain of AHRR (C-terminal). 
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